The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study
Abstract Background Dexamethasone has been widely used in treating severe COVID-19 patients due to its anti-inflammatory properties. However, its long-term impact on mortality remain unclear. Objective To evaluate the effect of dexamethasone on short-term (28-day) and long-term (1-year) mortality in...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-10216-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216594939052032 |
|---|---|
| author | Jian Zhao Hui Hua Jiang Hong Hong Wan Dan Liu Yi Zhao Yan Qing Chen Yuan Zhuo Chen |
| author_facet | Jian Zhao Hui Hua Jiang Hong Hong Wan Dan Liu Yi Zhao Yan Qing Chen Yuan Zhuo Chen |
| author_sort | Jian Zhao |
| collection | DOAJ |
| description | Abstract Background Dexamethasone has been widely used in treating severe COVID-19 patients due to its anti-inflammatory properties. However, its long-term impact on mortality remain unclear. Objective To evaluate the effect of dexamethasone on short-term (28-day) and long-term (1-year) mortality in hospitalized COVID-19 patients and to explore its efficacy across different respiratory support. Methods A retrospective cohort study was conducted using the MIMIC-IV (v3.0) database. A total of 576 confirmed COVID-19 patients were included, with 288 patients receiving dexamethasone and 288 not receiving it, matched by propensity scores. Survival analyses assessed the impact of dexamethasone on mortality, and subgroup analyses were performed based on the type of respiratory support received. Results After propensity score matching, dexamethasone treatment was associated with reduced mortality at both 28 days (adjusted HR 0.67, 95% CI 0.46–0.99, P = 0.045) and 1 year (adjusted HR 0.66, 95% CI 0.47–0.92, P = 0.014). Subgroup analysis revealed differential treatment effects by respiratory support type (P for interaction = 0.001 at 28 days and 0.004 at 1 year). The survival benefit was most pronounced in patients receiving NIV (28-day adjusted HR 0.15, 95% CI 0.05–0.42, P < 0.001) and significant in those receiving IMV (28-day adjusted HR 0.62, 95% CI 0.39–0.99, P = 0.045), while no significant benefit was observed in patients receiving oxygen therapy alone. Conclusion This retrospective study suggests that dexamethasone treatment was associated with reduced mortality in hospitalized COVID-19 patients, particularly in those receiving NIV or IMV. These findings add to the evidence supporting dexamethasone use in severe COVID-19 patients requiring respiratory support. |
| format | Article |
| id | doaj-art-28ca1ee1f22d4eb7bcd8fd4910a285c3 |
| institution | OA Journals |
| issn | 1471-2334 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-28ca1ee1f22d4eb7bcd8fd4910a285c32025-08-20T02:08:15ZengBMCBMC Infectious Diseases1471-23342024-11-012411910.1186/s12879-024-10216-3The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective studyJian Zhao0Hui Hua Jiang1Hong Hong Wan2Dan Liu3Yi Zhao4Yan Qing Chen5Yuan Zhuo Chen6Department of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineDepartment of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineDepartment of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineDepartment of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineDepartment of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineDepartment of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineDepartment of Emergency, Shanghai 10th People’s Hospital, Tongji University School of MedicineAbstract Background Dexamethasone has been widely used in treating severe COVID-19 patients due to its anti-inflammatory properties. However, its long-term impact on mortality remain unclear. Objective To evaluate the effect of dexamethasone on short-term (28-day) and long-term (1-year) mortality in hospitalized COVID-19 patients and to explore its efficacy across different respiratory support. Methods A retrospective cohort study was conducted using the MIMIC-IV (v3.0) database. A total of 576 confirmed COVID-19 patients were included, with 288 patients receiving dexamethasone and 288 not receiving it, matched by propensity scores. Survival analyses assessed the impact of dexamethasone on mortality, and subgroup analyses were performed based on the type of respiratory support received. Results After propensity score matching, dexamethasone treatment was associated with reduced mortality at both 28 days (adjusted HR 0.67, 95% CI 0.46–0.99, P = 0.045) and 1 year (adjusted HR 0.66, 95% CI 0.47–0.92, P = 0.014). Subgroup analysis revealed differential treatment effects by respiratory support type (P for interaction = 0.001 at 28 days and 0.004 at 1 year). The survival benefit was most pronounced in patients receiving NIV (28-day adjusted HR 0.15, 95% CI 0.05–0.42, P < 0.001) and significant in those receiving IMV (28-day adjusted HR 0.62, 95% CI 0.39–0.99, P = 0.045), while no significant benefit was observed in patients receiving oxygen therapy alone. Conclusion This retrospective study suggests that dexamethasone treatment was associated with reduced mortality in hospitalized COVID-19 patients, particularly in those receiving NIV or IMV. These findings add to the evidence supporting dexamethasone use in severe COVID-19 patients requiring respiratory support.https://doi.org/10.1186/s12879-024-10216-3DexamethasoneCOVID-19MortalityMIMIC-IVRetrospective studyRespiratory support |
| spellingShingle | Jian Zhao Hui Hua Jiang Hong Hong Wan Dan Liu Yi Zhao Yan Qing Chen Yuan Zhuo Chen The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study BMC Infectious Diseases Dexamethasone COVID-19 Mortality MIMIC-IV Retrospective study Respiratory support |
| title | The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study |
| title_full | The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study |
| title_fullStr | The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study |
| title_full_unstemmed | The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study |
| title_short | The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study |
| title_sort | impact of dexamethasone on short and long term mortality in hospitalized covid 19 patients a retrospective study |
| topic | Dexamethasone COVID-19 Mortality MIMIC-IV Retrospective study Respiratory support |
| url | https://doi.org/10.1186/s12879-024-10216-3 |
| work_keys_str_mv | AT jianzhao theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT huihuajiang theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT honghongwan theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT danliu theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT yizhao theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT yanqingchen theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT yuanzhuochen theimpactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT jianzhao impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT huihuajiang impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT honghongwan impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT danliu impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT yizhao impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT yanqingchen impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy AT yuanzhuochen impactofdexamethasoneonshortandlongtermmortalityinhospitalizedcovid19patientsaretrospectivestudy |